162 related articles for article (PubMed ID: 37158302)
21. Controlled multi-arm platform design using predictive probability.
Hobbs BP; Chen N; Lee JJ
Stat Methods Med Res; 2018 Jan; 27(1):65-78. PubMed ID: 26763586
[TBL] [Abstract][Full Text] [Related]
22. Bayesian single-arm phase II trial designs with time-to-event endpoints.
Wu J; Pan H; Hsu CW
Pharm Stat; 2021 Nov; 20(6):1235-1248. PubMed ID: 34085764
[TBL] [Abstract][Full Text] [Related]
23. Controlling the family-wise error rate in multi-arm, multi-stage trials.
Crouch LA; Dodd LE; Proschan MA
Clin Trials; 2017 Jun; 14(3):237-245. PubMed ID: 28545335
[TBL] [Abstract][Full Text] [Related]
24. Type I error rates of multi-arm multi-stage clinical trials: strong control and impact of intermediate outcomes.
Bratton DJ; Parmar MK; Phillips PP; Choodari-Oskooei B
Trials; 2016 Jul; 17(1):309. PubMed ID: 27369182
[TBL] [Abstract][Full Text] [Related]
25. A Bayesian Hybrid Adaptive Randomisation Design for Clinical Trials with Survival Outcomes.
Moatti M; Chevret S; Zohar S; Rosenberger WF
Methods Inf Med; 2016; 55(1):4-13. PubMed ID: 26404511
[TBL] [Abstract][Full Text] [Related]
26. Adaptive designs in critical care trials: a simulation study.
Li W; Cornelius V; Finfer S; Venkatesh B; Billot L
BMC Med Res Methodol; 2023 Oct; 23(1):236. PubMed ID: 37853343
[TBL] [Abstract][Full Text] [Related]
27. Adaptive treatment allocation and selection in multi-arm clinical trials: a Bayesian perspective.
Arjas E; Gasbarra D
BMC Med Res Methodol; 2022 Feb; 22(1):50. PubMed ID: 35184731
[TBL] [Abstract][Full Text] [Related]
28. Adding experimental treatment arms to multi-arm multi-stage platform trials in progress.
Burnett T; König F; Jaki T
Stat Med; 2024 Jun; ():. PubMed ID: 38852991
[TBL] [Abstract][Full Text] [Related]
29. A flexible multi-metric Bayesian framework for decision-making in Phase II multi-arm multi-stage studies.
Dufault SM; Crook AM; Rolfe K; Phillips PPJ
Stat Med; 2024 Feb; 43(3):501-513. PubMed ID: 38038137
[TBL] [Abstract][Full Text] [Related]
30. Bayesian designs of phase II oncology trials to select maximum effective dose assuming monotonic dose-response relationship.
Guo B; Li Y
BMC Med Res Methodol; 2014 Jul; 14():95. PubMed ID: 25074481
[TBL] [Abstract][Full Text] [Related]
31. Bayesian sample size determination for phase IIA clinical trials using historical data and semi-parametric prior's elicitation.
Berchialla P; Zohar S; Baldi I
Pharm Stat; 2019 Mar; 18(2):198-211. PubMed ID: 30440109
[TBL] [Abstract][Full Text] [Related]
32. Bayesian single-to-double arm transition design using both short-term and long-term endpoints.
Xu T; Shi H; Lin R
Pharm Stat; 2023; 22(4):588-604. PubMed ID: 36755420
[TBL] [Abstract][Full Text] [Related]
33. A comparison of clinical development pathways to advance tuberculosis regimen development.
Chang V; Phillips PPJ; Imperial MZ; Nahid P; Savic RM
BMC Infect Dis; 2022 Dec; 22(1):920. PubMed ID: 36494644
[TBL] [Abstract][Full Text] [Related]
34. BASIC: A Bayesian adaptive synthetic-control design for phase II clinical trials.
Jiang L; Thall PF; Yan F; Kopetz S; Yuan Y
Clin Trials; 2023 Oct; 20(5):486-496. PubMed ID: 37313712
[TBL] [Abstract][Full Text] [Related]
35. Hierarchical Bayesian clustering design of multiple biomarker subgroups (HCOMBS).
Kang D; S Coffey C; J Smith B; Yuan Y; Shi Q; Yin J
Stat Med; 2021 May; 40(12):2893-2921. PubMed ID: 33772843
[TBL] [Abstract][Full Text] [Related]
36. Optimal design of multi-arm multi-stage trials.
Wason JM; Jaki T
Stat Med; 2012 Dec; 31(30):4269-79. PubMed ID: 22826199
[TBL] [Abstract][Full Text] [Related]
37. Group sequential multi-arm multi-stage trial design with treatment selection.
Wu J; Li Y; Zhu L
Stat Med; 2023 May; 42(10):1480-1491. PubMed ID: 36808736
[TBL] [Abstract][Full Text] [Related]
38. A confidence function-based posterior probability design for phase II cancer trials.
Shan M
Pharm Stat; 2021 May; 20(3):485-498. PubMed ID: 33336856
[TBL] [Abstract][Full Text] [Related]
39. Sample size determination for a binary response in a superiority clinical trial using a hybrid classical and Bayesian procedure.
Ciarleglio MM; Arendt CD
Trials; 2017 Feb; 18(1):83. PubMed ID: 28231813
[TBL] [Abstract][Full Text] [Related]
40. Simulating and reporting frequentist operating characteristics of clinical trials that borrow external information: Towards a fair comparison in case of one-arm and hybrid control two-arm trials.
Kopp-Schneider A; Wiesenfarth M; Held L; Calderazzo S
Pharm Stat; 2024; 23(1):4-19. PubMed ID: 37632266
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
